TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07763015: Study of Resmetirom in Children and Adolescents With MASH

Sponsor: Madrigal Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 61 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07763015 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07763015 Rescue Dossier →